← FDA Drug Approvals (Drugs@FDA)
APREPITANT
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN · Approved 2026-03-05
Drug application
- FDA Application #
ANDA218851- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- APREPITANT
- Generic name
- Aprepitant
- Active ingredients
- APREPITANT
- Dosage form
- EMULSION
- Route
- INTRAVENOUS
- Marketing status
- Discontinued
- Sponsor
- MYLAN
- First approval
- 2026-03-05
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown